200 related articles for article (PubMed ID: 35301175)
1. TRIM66 hastens the malignant progression of non-small cell lung cancer via modulating MMP9-mediated TGF-β/SMAD pathway.
Chen W; Zhang Y; Fang Z; Qi W; Xu Y
Cytokine; 2022 May; 153():155831. PubMed ID: 35301175
[TBL] [Abstract][Full Text] [Related]
2. TRIM66 Promotes Malignant Progression of Non-Small-Cell Lung Cancer Cells via Targeting MMP9.
Xu Y; Yang Q; Fang Z; Tan X; Zhang M; Chen W
Comput Math Methods Med; 2022; 2022():6058720. PubMed ID: 35912155
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-422a functions as a tumor suppressor in non-small cell lung cancer through SULF2-mediated TGF-β/SMAD signaling pathway.
Li WQ; Zhang JP; Wang YY; Li XZ; Sun L
Cell Cycle; 2019 Aug; 18(15):1727-1744. PubMed ID: 31204561
[TBL] [Abstract][Full Text] [Related]
4. TRIM66 promotes malignant progression of hepatocellular carcinoma by inhibiting E-cadherin expression through the EMT pathway.
Zhang HG; Pan YW; Feng J; Zeng CT; Zhao XQ; Liang B; Zhang WW
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2003-2012. PubMed ID: 30915743
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of TRIM66 inhibits malignant behavior and epithelial-mesenchymal transition in non-small cell lung cancer.
Dai HY; Ma Y; Da Z; Hou XM
Pathol Res Pract; 2018 Aug; 214(8):1130-1135. PubMed ID: 29929749
[TBL] [Abstract][Full Text] [Related]
6. CUEDC1 inhibits epithelial-mesenchymal transition via the TβRI/Smad signaling pathway and suppresses tumor progression in non-small cell lung cancer.
Cui Y; Song Y; Yan S; Cao M; Huang J; Jia D; Liu Y; Zhang S; Fan W; Cai L; Li C; Xing Y
Aging (Albany NY); 2020 Oct; 12(20):20047-20068. PubMed ID: 33099540
[TBL] [Abstract][Full Text] [Related]
7. TRIM66 overexpresssion contributes to osteosarcoma carcinogenesis and indicates poor survival outcome.
Chen Y; Guo Y; Yang H; Shi G; Xu G; Shi J; Yin N; Chen D
Oncotarget; 2015 Sep; 6(27):23708-19. PubMed ID: 26247633
[TBL] [Abstract][Full Text] [Related]
8. Forkhead box L2 is a target of miR-133b and plays an important role in the pathogenesis of non-small cell lung cancer.
Li J; Gao L; Wang A; Qian H; Zhu J; Ji S; Chen J; Liu Z; Ji C
Cancer Med; 2023 Apr; 12(8):9826-9842. PubMed ID: 36846934
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-527 inhibits TGF-β/SMAD induced epithelial-mesenchymal transition via downregulating SULF2 expression in non-small-cell lung cancer.
Huo W; Zhu XM; Pan XY; Du M; Sun Z; Li ZM
Math Biosci Eng; 2019 May; 16(5):4607-4621. PubMed ID: 31499680
[TBL] [Abstract][Full Text] [Related]
10. KIFC1 aggravates non-small-cell lung cancer cell proliferation and metastasis via provoking TGF-β/SMAD signal.
Liu Y; Ye W; Miao X; Wang X
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):293-299. PubMed ID: 38279416
[TBL] [Abstract][Full Text] [Related]
11. POM121 promotes proliferation and metastasis in non-small-cell lung cancer through TGF-β/SMAD and PI3K/AKT pathways.
Guan L; Zhang L; Wang T; Jia L; Zhang N; Yan H; Zhao K
Cancer Biomark; 2021; 32(3):293-302. PubMed ID: 34151840
[TBL] [Abstract][Full Text] [Related]
12. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
[TBL] [Abstract][Full Text] [Related]
13. Chinese medicine Bu-Fei decoction attenuates epithelial-mesenchymal transition of non-small cell lung cancer via inhibition of transforming growth factor β1 signaling pathway in vitro and in vivo.
He XR; Han SY; Li XH; Zheng WX; Pang LN; Jiang ST; Li PP
J Ethnopharmacol; 2017 May; 204():45-57. PubMed ID: 28412214
[TBL] [Abstract][Full Text] [Related]
14. Repression of TIF1γ by SOX2 promotes TGF-β-induced epithelial-mesenchymal transition in non-small-cell lung cancer.
Wang L; Yang H; Lei Z; Zhao J; Chen Y; Chen P; Li C; Zeng Y; Liu Z; Liu X; Zhang HT
Oncogene; 2016 Feb; 35(7):867-77. PubMed ID: 25961934
[TBL] [Abstract][Full Text] [Related]
15. RNA demethylase ALKBH5 inhibits TGF-β-induced EMT by regulating TGF-β/SMAD signaling in non-small cell lung cancer.
Sun Z; Su Z; Zhou Z; Wang S; Wang Z; Tong X; Li C; Wang Y; Chen X; Lei Z; Zhang HT
FASEB J; 2022 May; 36(5):e22283. PubMed ID: 35344216
[TBL] [Abstract][Full Text] [Related]
16. MiR-145 and miR-203 represses TGF-β-induced epithelial-mesenchymal transition and invasion by inhibiting SMAD3 in non-small cell lung cancer cells.
Hu H; Xu Z; Li C; Xu C; Lei Z; Zhang HT; Zhao J
Lung Cancer; 2016 Jul; 97():87-94. PubMed ID: 27237033
[TBL] [Abstract][Full Text] [Related]
17. RNF111/Arkadia is regulated by DNA methylation and affects TGF-β/Smad signaling associated invasion in NSCLC cells.
Chen H; Yang T; Lei Z; Wang L; Yang H; Tong X; Yang WT; Zhao J; Gu Y; Chen Y; Zhang HT
Lung Cancer; 2015 Oct; 90(1):32-40. PubMed ID: 26238425
[TBL] [Abstract][Full Text] [Related]
18. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis.
Wang L; Shang X; Feng Q
Cancer Biol Ther; 2019; 20(3):261-271. PubMed ID: 30481109
[TBL] [Abstract][Full Text] [Related]
19. Long noncoding RNA SNHG7 contributes to cell proliferation, migration, invasion and epithelial to mesenchymal transition in non-small cell lung cancer by regulating miR-449a/TGIF2 axis.
Pang L; Cheng Y; Zou S; Song J
Thorac Cancer; 2020 Feb; 11(2):264-276. PubMed ID: 31793741
[TBL] [Abstract][Full Text] [Related]
20. ADAMTS1 induces epithelial-mesenchymal transition pathway in non-small cell lung cancer by regulating TGF-β.
Hu X; Jiang C; Hu N; Hong S
Aging (Albany NY); 2023 Mar; 15(6):2097-2114. PubMed ID: 36947712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
